10x Genomics, SCRUM Collaborate
News Sep 16, 2016
10x Genomics, Inc. has announced that it has entered into distribution agreement with SCRUM Inc. to bring the Chromium™ System and associated products to the rapidly expanding Japanese market. “With the addition of our new Japanese partner, 10x has successfully inked distribution arrangements throughout the Asia Pacific region, a growing market that is hungry for new and more powerful sequencing solutions,” said Serge Saxonov, Ph.D., co-founder and chief executive officer of 10x Genomics.
“Having analyzed a number of exceptional partnering opportunities in the region, we are pleased to be working with SCRUM Inc. to deliver these new capabilities to our current and future customers in Japan.” The company’s recently launched Chromium System is a microfluidics-based molecular barcoding system, built upon their proprietary GemCode™ Technology. The single instrumentation system can run multiple, powerful applications, including the Chromium Genome and Exome Solutions, which both provide novel long-range genomic data called “linked-reads.”
The Chromium workflows utilize a customer’s existing short-read sequencer, and enable more expansive characterization of previously inaccessible genomic information. In addition, the Chromium Single Cell Solution allows for high-throughput, deep profiling of complex cell populations through single-cell gene expression analysis. “The value of 10x Genomics’ platform has already been well validated by many genomic researchers and commercial research organizations,” said Takemitsu Furuta, executive director, business development of SCRUM.
“We recently held a Chromium System seminar and received overwhelmingly positive feedback from potential users, which reiterates our confidence that this system has the ability to positively impact the efficiency and quality of our customers’ research.” In May of this year, 10x announced key distribution agreements with MDxK, Inc., Millennium Science Pty Ltd, Research Instruments Pte Ltd and Star Research Technology Ltd., in South Korea, Australia and New Zealand, Southeast Asia and China respectively.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE